Evidence map›Paper›PMID 39548764›Full record

ArticleCancer medicine2024

Calcium Channel Blocker Versus Renin-Angiotensin System Inhibitor in Risk of Kidney Cancer Among Patients With Hypertension: A Propensity Score-Matched Cohort Study.

Minji Jung, Shufeng Li, Zhengyi Deng, Jinhui Li, Mingyi Li, Satvir Basran, Marvin E Langston, Benjamin I Chung

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Minji JungDepartment of Urology, Stanford University Medical Center, Stanford, California, USA.ORCID https://orcid.org/0000-0002-5489-827X
Shufeng LiDepartment of Urology, Stanford University Medical Center, Stanford, California, USA.
Zhengyi DengDepartment of Urology, Stanford University Medical Center, Stanford, California, USA.ORCID https://orcid.org/0000-0002-9456-723X
Jinhui LiDepartment of Urology, Stanford University Medical Center, Stanford, California, USA.
Mingyi LiDepartment of Urology, Stanford University Medical Center, Stanford, California, USA.ORCID https://orcid.org/0000-0001-9727-7636
Satvir BasranDepartment of Urology, Stanford University Medical Center, Stanford, California, USA.
Marvin E LangstonDepartment of Epidemiology and Population Health, School of Medicine, Stanford University, Stanford, California, USA.
Benjamin I ChungDepartment of Urology, Stanford University Medical Center, Stanford, California, USA.

Funding

Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
NCATS NIH HHS UL1 TR003142
6 · The paper itself

Abstract

backgroundUse of antihypertensive medications could be associated with an increased risk of kidney cancer. Despite their various mechanisms of action, whether this association differs between different classes of medications remains unclear.

objectiveThe objective of this study is to compare the risk of kidney cancer between first-line treatment options of antihypertensive medications in a hypertensive population.

methodIn this retrospective cohort study, we used the MarketScan Databases (2007-2021). We included individuals older than 30 years of age with a diagnosis of hypertension who received first-line medications for hypertension, which included three classes: angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and dihydropyridine calcium channel blockers (dCCB). We applied a propensity score matching method and created three separate cohorts: (1) ARB versus ACEI, (2) dCCB versus ACEI, and (3) dCCB versus ACEI. For non-dCCB, we repeated the analyses. The primary outcome was kidney cancer incidence. To assess kidney cancer risk, we applied multivariable conditional Cox proportional hazards models.

resultsIn the first cohort, ARB use was associated with an increased risk of kidney cancer compared to ACEI use (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.02-1.18). In the second cohort, dCCB use was associated with an increased risk of kidney cancer compared to ACEI use (HR 1.29, 95% CI 1.18-1.40). In the third cohort, dCCB use was associated with a higher risk of kidney cancer compared to ARB use (HR 1.17, 95% CI 1.08-1.28). Null association was shown when comparing non-dCCB with ACEI or ARB use.

conclusionUse of dCCB showed a higher risk of kidney cancer compared to ACEI or ARB use in patients with hypertension.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCalcium Channel BlockersHypertensionKidney NeoplasmsPropensity ScoreAdultAgedAntihypertensive AgentsFemaleHumansIncidenceMaleMiddle AgedRenin-Angiotensin SystemRetrospective StudiesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsCalcium Channel Blockersantihypertensive drugscalcium channel blockerhypertensionkidney cancerrenin–angiotensin system inhibitor

Identifiers

PMID39548764
PMCPMC11568363

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.